Quick Answer
GILEAD SCIENCES, INC. reported Total Revenue of $29.44 billion for fiscal year 2025.
GILEAD SCIENCES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $29.44B +2.4% |
$28.75B +6.0% |
$27.12B -0.6% |
$27.28B -0.1% |
$27.30B +10.6% |
$24.69B +10.0% |
| Revenue (ASC 606) | $29.44B +2.4% |
$28.75B +6.0% |
$27.12B -0.6% |
$27.28B -0.1% |
$27.30B +10.6% |
$24.69B +10.0% |
| Net Income | $8.51B +1672.9% |
$480.00M -91.5% |
$5.67B +23.4% |
$4.59B -26.2% |
$6.22B +4961.0% |
$123.00M -97.7% |
| Diluted EPS | $6.78 +1684.2% |
$0.38 -91.6% |
$4.50 +23.6% |
$3.64 -26.2% |
$4.93 +4830.0% |
$0.10 -97.6% |
| Total Assets | $59.02B +0.0% |
$58.99B -5.0% |
$62.12B -1.7% |
$63.17B -7.0% |
$67.95B -0.7% |
$68.41B +11.0% |
| Cash and Equivalents | — | — | — | $5.41B +1.4% |
$5.34B -11.0% |
$6.00B -48.4% |
| Long-Term Debt | $22.13B -11.1% |
$24.90B +7.4% |
$23.19B +1.0% |
$22.96B -8.8% |
$25.18B -12.1% |
$28.64B +29.7% |
| Stockholders Equity | $22.70B +17.4% |
$19.33B -15.3% |
$22.83B +7.5% |
$21.24B +0.8% |
$21.07B +15.8% |
$18.20B -19.2% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | $10.02B +503.0% |
$1.66B -78.1% |
$7.61B +3.8% |
$7.33B -26.1% |
$9.92B +143.6% |
$4.07B -5.0% |
| Shares Outstanding | 1.24B -0.4% |
1.25B +0.0% |
1.25B -0.1% |
1.25B -0.6% |
1.25B +0.0% |
1.25B -0.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $7.77B | +3.0% | +9.7% |
| Revenue (ASC 606) | September 30, 2025 | $7.77B | +3.0% | +9.7% |
| Net Income | September 30, 2025 | $3.05B | +143.6% | +55.7% |
| Diluted EPS | September 30, 2025 | $2.43 | +143.0% | +55.8% |
| Total Assets | September 30, 2025 | $58.53B | +7.4% | +5.0% |
| Cash and Equivalents | June 30, 2019 | $11.24B | -15.1% | -33.6% |
| Long-Term Debt | September 30, 2025 | $22.14B | +3.3% | -0.0% |
| Stockholders Equity | September 30, 2025 | $21.54B | +16.6% | +9.5% |
| R&D Expense | March 31, 2020 | $1.10B | +4.2% | -77.9% |
| Operating Income | September 30, 2025 | $3.33B | +274.7% | +34.5% |
| Shares Outstanding | September 30, 2025 | 1.24B | -0.3% | +0.0% |
- GILEAD SCIENCES, INC. reported Total Revenue of $29.44 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +2.4% in Total Revenue compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Revenue (ASC 606) of $29.44 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +2.4% in Revenue (ASC 606) compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Net Income of $8.51 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +1672.9% in Net Income compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Diluted EPS of $6.78 per share for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +1684.2% in Diluted EPS compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Total Assets of $59.02 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +0.0% in Total Assets compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Cash and Equivalents of $5.41 billion for fiscal year 2022.
- GILEAD SCIENCES, INC. showed an increase of +1.4% in Cash and Equivalents compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Long-Term Debt of $22.13 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed a decrease of -11.1% in Long-Term Debt compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Stockholders Equity of $22.70 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +17.4% in Stockholders Equity compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported R&D Expense of $9.11 billion for fiscal year 2019.
- GILEAD SCIENCES, INC. showed an increase of +81.5% in R&D Expense compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Operating Income of $10.02 billion for fiscal year 2025.
- GILEAD SCIENCES, INC. showed an increase of +503.0% in Operating Income compared to the prior fiscal year.
- GILEAD SCIENCES, INC. reported Shares Outstanding of 1.24 billion shares for fiscal year 2025.
- GILEAD SCIENCES, INC. showed a decrease of -0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: